OSE Immunotherapeutics’ Immuno-Inflammation area consists of two clinical-stage programs with promising candidates focusing on two different pathways:

– The IL-7 pathway with OSE-127 (Lusvertikimab)

OSE-127 in clinical Phase in 2 in ulcerative colitis

– The CD28 pathway with FR104

FR104 is in clinical Phase 1/2 in kidney transplant in partnership with Veloxis Pharmaceuticals, Inc.

To receive OSE Immunotherapeutics’ latest news